1a:I[176881,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1c:I[60790,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1d:I[691915,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1e:I[202116,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js","/_next/static/chunks/0tni2t5hh-dby.js"],"default"] 1b:T416,

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.

The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.

It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

The company is headquartered in Toronto, Canada.

No Dividend Data Available